BY 101921
Alternative Names: BY-101921Latest Information Update: 11 Jul 2024
At a glance
- Originator Chengdu Baiyu Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 7 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 04 Jun 2024 BY 101921 is available for licensing as of 04 Jun 2024. https://www.baiyu.cn/english.php?m=study&a=index (Chengdu Baiyu Pharmaceutical pipeline, June 2024)
- 04 Jun 2024 Chengdu Baiyu Pharmaceutical plans to launch BY 101921 in 2026 (Chengdu Baiyu Pharmaceutical pipeline, June 2024)
- 29 May 2024 Adverse events, pharmacokinetics, pharmacodynamics data from a preclinical trials in Solid tumours presented at the 2024 American Society of Clinical Oncology annual meeting (ASCO-2024)